Venclose and Viant have forged a partnership to manufacture Venclose’s RF ablation catheter in Viant’s ISO-certified facilities.
Venclose’s system will be moved to Viant’s manufacturing facility in Costa Rica and will take place by the third quarter of this year.
“With the innovative Venclose System’s first year of commercialization far surpassing our expectations, we realized the need to have a manufacturing partner with the ability to keep pace with our future growth and production scale. Based on an initial annual production capacity of over 250,000 catheters and the future ability to triple that volume, Viant ensures that our company can meet the accelerating demands of our growing customer base,” Jerry Gibson, chairman and CEO of Venclose, said in a press release. “Our confidence in choosing Viant is supported by its decades of industry leadership including demonstrated expertise in manufacturing the highest quality minimally invasive, thermal ablation catheter products.”
The VEnclose system is an endogenous RF ablation system that is designed to close a damaged vein and restore healthy blood flow in patients who have venous reflux disease.
“We take pride in being able to help our customers bring their technologies to life,” Viant CEO Brian King said. “Our ability to scale up as well as our robust supply chain and focus on operational excellence offers companies like Venclose the consistent level of quality and performance that they need to be successful.”
